Shah Jatin 4
4 · Karyopharm Therapeutics Inc. · Filed Feb 9, 2022
Insider Transaction Report
Form 4
Shah Jatin
EVP, Chief Medical Officer
Transactions
- Sale
Common Stock
2022-02-07$9.86/sh−1,704$16,805→ 130,756 total
Footnotes (3)
- [F1]This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
- [F2]The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 7, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.
- [F3]Includes 1,323 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on October 31, 2021.